12月9日，惠泰医疗公告称，公司拟以集中竞价交易方式回购股份，资金总额不低于2亿元，不超过2.5 亿元。回购价格不超过315元/股，回购期限为自董事会审议通过之日起10个月内。回购股份将在未来适 宜时机用于员工持股计划或股权激励。 点评：惠泰医疗用自有资金回购股份用于员工激励，既彰显了对行业前景和自身发展的信心，也能绑定 核心员工利益。回购资金虽对公司正常经营无影响，但需留意股价超上限等可能导致回购受阻的风险。 丨2025年12月10日星期三丨 NO.1 莱茵生物控股股东筹划控制权变更并拟购买北京金康普至少80%股权 12月9日，莱茵生物公告称，收到控股股东、实际控制人秦本军的通知，秦本军正在筹划公司控制权变 更事宜，拟向交易对手方协议转让其持有的部分公司股份并放弃其持有的部分公司股份表决权。目前相 关各方已就该事项签署了《控制权变更意向协议》，具体交易方案、协议条款等尚需进一步论证和磋 商，届时将以各方签订的正式交易协议为准，上述事项可能导致公司控股股东及实际控制人发生变更。 同时，公司拟发行股份及支付现金购买北京金康普食品科技有限公司至少80%股权，并向广州德福营养 发行股份募集配套资金。 点评：莱茵生物 ...

每经头条（nbdtoutiao）——处方药变"瘾品"：国内首次报告普瑞巴林滥用致成瘾病例，网络平台暴 露"无病历可购药"漏洞，列管与否尚需科学考量 （记者 王晓波） 每经AI快讯，丰原药业（SZ 000153，收盘价：6.62元）12月9日晚间发布公告称，公司收到股东蚌埠涂 山企业管理有限公司函告，获悉其所持有本公司的部分股份进行质押，本次质押3236万股。截至本公告 日，安徽省无为制药厂累计质押股数为3162万股，占其所持股份比例为63.01%。马鞍山丰原企业管理 有限公司累计质押股数为1412万股，占其所持股份比例为99.95%。蚌埠涂山企业管理有限公司累计质 押股数为3236万股，占其所持股份比例为90.57%。 2025年1至6月份，丰原药业的营业收入构成为：药品零售流通占比63.78%，药品生产制造占比34.4%， 其他业务占比1.82%。 截至发稿，丰原药业市值为31亿元。 ...

股票简称：丰原药业 股票代码：000153 公告编号：2025-043 | | | | | | | | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 本次质押 | 本次质押 | 占其所 | 占公司 | 情况 | | 情况 未质押 | | | 股东名称 | 持股数量 （股） | 持股比 例（%） | 前质押股 份数量 | 后质押股 份数量 | 持股份 比例 | 总股本 比例 | 已质押股 份限售和 | 占已质 押股份 | 股份限 | 占未质 押股份 | | | | | （股） | （股） | （%） | （%） | 冻结、标记 | 比例 | 售和冻 | 比例 | | | | | | | | | 数量（股） | （%） | 结数量 （股） | （%） | | 安徽省无为 制药厂 | 50,178,992 | 10.79 | 31,620,000 | 31,620,000 | 63.01 | 6.80 | 0 | 0 | 0 | 0 | | 马鞍山丰原 企业管理有 限公司 ...

Group 1 - The announcement details that Anhui Fengyuan Pharmaceutical Co., Ltd. has received notification from a shareholder regarding the pledge of part of their shares [1] - The pledged shares do not involve significant asset restructuring or performance compensation obligations [1] - The company will continue to monitor the shareholder pledge situation and related risks, ensuring timely information disclosure as required [3] Group 2 - The shareholders and their concerted actions are associated with subsidiaries of Anhui Fengyuan Group Co., Ltd., as defined by the regulations on listed company acquisitions [3] - The announcement includes a reference to the securities pledge registration certificate from China Securities Depository and Clearing Corporation Limited [4]

（编辑 姚尧） 证券日报网讯 11月26日晚间，丰原药业发布公告称，近日，安徽丰原药业股份公司（以下简称"公 司"）收到股东函告，获悉其所持有本公司的部分股份进行质押，合计质押股份数量为45，740，000 股。 ...

Group 1 - Fengyuan Pharmaceutical (SZ 000153) announced that as of the date of the announcement, Anhui Wuwei Pharmaceutical Factory has pledged a total of 31.62 million shares, accounting for 63.01% of its holdings [1] - Ma'anshan Fengyuan Enterprise Management Co., Ltd. has pledged a total of 14.12 million shares, accounting for 99.95% of its holdings [1] - For the first half of 2025, Fengyuan Pharmaceutical's revenue composition is as follows: 63.78% from pharmaceutical retail and distribution, 34.4% from pharmaceutical manufacturing, and 1.82% from other businesses [1] Group 2 - As of the report, Fengyuan Pharmaceutical has a market capitalization of 3.1 billion yuan [1]

股票简称：丰原药业 股票代码：000153 公告编号：2025-042 安徽丰原药业股份有限公司 关于股东部分股份质押的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 一、本次股份质押的基本情况 近日，安徽丰原药业股份公司（以下简称"公司"）收到股东函告，获悉其所持 有本公司的部分股份进行质押，具体情况如下： | 股东名称 | 是否为控股股 东或第一大股 东及其一致行 | 本次质押数 量（股） | 占其所 持股份 比例 | 占公 司总 股本 | 是否 为限 售股 | 是否为 补充质 | 质押 起始日 | 质押 到期日 | 质权人 | 质押 用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 动人 | | | 比例 | | 押 | | | | | | | | | （%） | （%） | | | | | | | | 安徽省无为 制药厂 | 是 | 31,620,000 | 63.01 | 6.80 | 否 | 否 | 2025.11.25 | 2027.12. ...

Core Points - The company held its second extraordinary general meeting of shareholders in 2025 on November 11, 2025, with no new proposals or changes to previous resolutions [1][2] - The meeting was conducted in compliance with relevant laws and regulations [8][27] Meeting Details - The meeting took place at the company's headquarters in Hefei, Anhui, starting at 14:30 [4][3] - A combination of on-site and online voting was utilized for the meeting [5] - The total number of shares represented at the meeting was 128,275,798, accounting for 27.5996% of the total voting shares [9] Resolutions Passed - The proposal to repurchase and cancel part of the restricted stock was approved, with 98.8459% of the votes in favor [11] - The amendment to the company's articles of association was approved with 98.8278% support [14] - The revision of the shareholders' meeting rules was passed with 98.7505% approval [17] - The amendment to the board meeting rules received 98.8231% approval [20] - The revision of the independent director working system was approved with 98.7512% support [23] Legal Opinions - The meeting was witnessed by lawyers from Anhui Jingqiao Law Firm, confirming that the meeting's procedures and resolutions were in accordance with the law [27] Additional Information - The company announced plans to repurchase and cancel 88,200 shares of restricted stock due to the departure of one employee and the failure of two others to meet performance criteria [29][30] - Following the repurchase, the company's registered capital will decrease by 88,200 yuan [30]

Core Viewpoint - Anhui Fengyuan Pharmaceutical Co., Ltd. has revised its articles of association, focusing on capital structure, governance mechanisms, profit distribution, and risk control, with a registered capital set at 464.685522 million yuan [1][7]. Capital Structure and Registered Capital Adjustment - The current total share capital of Fengyuan Pharmaceutical is 46,468.5522 million shares, all of which are ordinary shares. The share capital has evolved from an initial 20.604 million shares in 1997 to the current scale through multiple capital increases and adjustments [2]. Corporate Governance Structure Optimization - The new articles designate the general manager as the legal representative, replacing the previous arrangement where the chairman held this position. This change aims to enhance management accountability and decision-making efficiency. The board consists of six directors, including two independent directors and one employee representative, with established committees for audit, nomination, and remuneration [3]. Shareholder Rights and Decision-Making Mechanism Improvement - The revised articles strengthen protections for minority shareholders, requiring related shareholders to abstain from voting on related party transactions. Major decisions require a special resolution from the shareholders' meeting, with at least two-thirds of the voting rights [4]. Profit Distribution Policy Clarification - The new articles specify that the company will prioritize cash dividends, with a minimum annual cash dividend ratio of 10% of distributable profits when conditions are met. Over three years, cumulative cash dividends should not be less than 30% of the average annual distributable profits [5][6]. Risk Control and Compliance Management - The articles stipulate that any external guarantees exceeding 50% of the latest audited net assets or single guarantees exceeding 10% must be approved by the shareholders' meeting. The company can repurchase shares under certain conditions, with a limit of 10% of the total issued capital, requiring a two-thirds majority of the board [7].

具体内容详见公司于 2025 年 10 月 24 日刊登在《中国证券报》《证券时报》《证 券日报》《上海证券报》、巨潮资讯网（http://www.cninfo.com.cn）的相关公告。 2025 年 11 月 11 日，公司召开 2025 年第二次临时股东会，审议通过《关于回购 注销部分限制性股票的议案》。 公司实施回购注销上述激励对象已获授但尚未解除限售的限制性股票 88,200 股 后，公司注册资本将减少 88,200 元。公司将及时披露回购注销完成公告，并于本次 回购注销完成后依法履行相应注册资本变更的程序。 安徽丰原药业股份有限公司 关于回购注销部分限制性股票减资暨通知债权人公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述或 者重大遗漏。 安徽丰原药业股份有限公司（以下简称"公司"）第十届董事会第三次会议于 2025 年 10 月 22 日在公司办公楼第一会议室召开。本次会议审议通过了《关于回购注销 部分限制性股票的议案》，同意回购注销 1 名因主动离职不再具备激励资格和 2 名因 考核不合格未满足解除限售条件的 3 名激励对象已获授但尚未解除限售的 88,20 ...